Redwood City, Calif.-based Minerva filed a complaint in federal court in San Francisco yesterday, and said it could seek an injunction to block the US sales of the NovaSure Advanced system, which is designed to treat heavy menstrual bleeding.
Hologic began selling the NovaSure Advanced endometrial ablation system in the US on February, and originally launched the device in Europe, Canada and Australia in 2016. The device is a 2nd-generation version of the device, which originally launched in 2001.
Minerva’s rival device, the Aurora endometrial ablation system, won pre-market approval from the FDA in July 2015, but the company has not yet launched the device.
Last December, Minerva reported a funding round worth $16.7 million and said it wanted to raise $10 million more to support the system.
Material from Reuters was used in this report.